Lung adenocarcinoma
Conditions
Interventions
Experimental group (non-shedding tumor group):NA
Control group (shedding tumor group):NA
Sponsors
Tianjin Medical University General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients aged >=18 years; gender is not restricted. 2. Patients diagnosed with lung adenocarcinoma staged 2 cm = 12 weeks. 8. Adequate cardiopulmonary function, bone marrow hematopoietic function, and liver and kidney organ function. 9. Participants must understand the requirements and content of the clinical trial and provide a handwritten, signed, and dated informed consent form before the clinical trial and sample collection.
Exclusion criteria
Exclusion criteria: 1. Chest CT or PET-CT shows multiple primary lung cancers. 2. Chest CT (PET-CT) shows the mass is traversed by segmental or larger pulmonary veins. 3. Neoadjuvant therapy (chemotherapy or immunotherapy) prior to radical surgery. 4. Currently diagnosed with malignant tumors in other parts of the body or having had other invasive malignant tumors within the past 5 years. 5. Uncontrolled infections or active infections requiring intravenous antibiotics, antivirals, or antifungal medications. 6. Major surgery within 28 days prior to screening. 7. History of interstitial lung disease, non-infectious pneumonia, or poorly controlled conditions (including pulmonary fibrosis, acute lung diseases, etc.). 8. Severe, uncontrolled, or active cardiovascular and cerebrovascular diseases, including but not limited to myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack within 6 months before the first dose; congestive heart failure (NYHA class > II); long QT syndrome; complete left bundle branch block; third-degree atrioventricular block; or other arrhythmias requiring treatment. 9. Uncontrolled hypertension (i.e., blood pressure >=150/100 mmHg despite medication). 10. Active primary immunodeficiency, known HIV infection, active hepatitis B, or hepatitis C infection. 11. If previously participated in other clinical trials, the investigator and clinical trial physician will jointly assess eligibility for enrollment. 12. Based on the investigator’s judgment, the participant’s compliance with the clinical study is insufficient or unable to adhere to the study’s restrictions and requirements. 13. Pregnant or breastfeeding women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Multi-omics profiling of tumor tissue (genomics, proteomics, transcriptomics, and immune microenvironment); | — |
Secondary
| Measure | Time frame |
|---|---|
| Genetic mutations of tumor tissue; | — |
Countries
China
Contacts
Public ContactSong Xu
Tianjin Medical University General Hospital
Outcome results
None listed